Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Clear clinical and laboratory diagnosis of HAE~* Plasma level of functional C1INH of less than 50% of normal~* Acute abdominal, urogenital, peripheral, and/or oro-facial/pharyngeal/laryngeal HAE attack~Main Exclusion Criteria:~* Acquired angioedema~* Pregnancy or breastfeeding~* Treatment with any investigational drug within prior 30 days~* Body weight \>120 kg

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100 IU/kg rhC1INH (Type: EXPERIMENTAL): 100 IU/kg Recombinant human C1 inhibitor
- 50 IU/kg rhC1INH (Type: EXPERIMENTAL): 50 IU/kg Recombinant human C1 inhibitor
- Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).